Focus on Japanese Pharma/Biotech Deals
A statistical breakdown of Japanese deals by payment type and rights shows that Japanese are still fundamentally regional players in their ambitions.
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.